LBA65IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. (23rd October 2018) - Socinski, M A; Rittmeyer, A; Shapovalov, D; Orlandi, F; McCleod, M; Soo, R A; Palmero, R; Kozuki, T; Migliorino, M R; Koynov, K D; Berard, H; Hughes, B G M; et al.